Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. [electronic resource]
Producer: 20130110Description: 2650-7 p. digitalISSN:- 1528-0020
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Female
- Follow-Up Studies
- Humans
- International Agencies
- Lymphoma, Follicular -- drug therapy
- Male
- Middle Aged
- Polymorphism, Single Nucleotide -- genetics
- Prognosis
- Prospective Studies
- Receptors, IgG -- genetics
- Remission Induction
- Rituximab
- Survival Rate
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.